CONTROL, LIPID SERUM

The contract solicits CONTROL, LIPID SERUM, a liquid quality control material designed to monitor lipid analytes in human serum using Piccolo Xpress diagnostic systems. The item is supplied as a unit of issue (VI) consisting of 12 vials per package, with each vial containing 500 milliliters, equally divided between normal and abnormal controls. The product must be stored and shipped frozen at temperatures between -15°C and -25°C (-5°F to -13°F), with a strict shelf life of two months that is non-extendable; no more than one week may elapse between the date of manufacture and delivery to the government. Packaging and labeling must comply with Medical Marking Standard No. 1 (MMS No. 1), superseding MIL-STD-129, which requires all vials to be marked with the date of manufacture, expiration or retest date, and the contract and lot numbers, following MMS1C guidelines. The material must be packaged in sealed, commercial-grade containers suitable for protection against damage and shipped in exterior containers that ensure safe, cost-effective delivery via common carrier to Fort Polk, LA, with FOB destination terms meaning risk transfers upon delivery. The solicitation incorporates numerous Federal Acquisition Regulation (FAR) and Defense Federal Acquisition Regulation Supplement (DFARS) clauses covering critical compliance areas, including cybersecurity safeguards for covered defense information under NIST SP 800-171, prohibition of hazardous materials without proper Safety Data Sheets and hazard labeling, mandatory use of U.S.-flag vessels for ocean transport, and electronic invoicing through Wide Area WorkFlow (WAWF). Contractors must ensure compliance with DLA’s technical and quality requirements as defined in the DLA Master List, submit appropriate UEI and CAGE codes, and provide accurate representations of business size and socioeconomic status. Acceptance occurs at the destination, and inspection is governed by FAR 52.246-2. Proposals must be submitted electronically via DIBBS by the closing date of May 26, 2026, with no physical submissions permitted, and pricing is to be proposed by offerors since no unit price is stipulated. The product is part of a medical acquisition under NAICS code 621410, and all packaging, preservation, and marking must conform to MIL-STD-2073-1E and related supplemental instructions, with flow-down obligations applied to subcontractors providing commercial